Palvella Therapeutics Receives FDA Approval for QTORIN™ Rapamycin
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 11 2025
0mins
Palvella Therapeutics Inc's stock rose by 8.70% as it reached a 20-day high amid a challenging market environment where the Nasdaq-100 is down 1.06% and the S&P 500 is down 0.16%.
The company announced that its New Drug Application (NDA) for QTORIN™ rapamycin has received FDA rolling review approval, which is expected to expedite treatment options for over 30,000 patients with microcystic lymphatic malformations. Following positive results from the Phase 3 SELVA trial, Palvella's CEO highlighted the commitment to advancing QTORIN™ as the first FDA-approved therapy for this condition, addressing a significant unmet medical need.
This FDA approval not only enhances Palvella's competitive position in the market but also signifies a crucial step towards providing effective treatment options for patients, particularly children, suffering from microcystic lymphatic malformations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PVLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PVLA
Wall Street analysts forecast PVLA stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 136.200
Low
133.00
Averages
182.20
High
212.00
Current: 136.200
Low
133.00
Averages
182.20
High
212.00
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palvella Therapeutics Executive Exercises Stock Options
- Stock Option Exercise: Kathleen Goin, COO of Palvella Therapeutics, exercised and sold 4,302 common shares on June 17, 2026, for approximately $476,000 at an average price of $110.73 per share, indicating executive confidence in the company's future stock performance.
- FDA Review Progress: The company recently received FDA rolling review for its New Drug Application for QTORIN rapamycin, suggesting a positive regulatory outlook for its rare skin disease treatment, which could expedite the approval process and enhance market competitiveness.
- Strong Market Performance: Palvella's shares have surged nearly 620% over the past year, reflecting investor optimism regarding its lead therapy QTORIN, further solidifying the company's position in the rare disease treatment market.
- Strategic Market Shift: The recent move of Palvella's shares to the Nasdaq Global Market is expected to increase the company's visibility, aiding in garnering more attention and investment for its potential first-in-disease therapies.
See More
Palvella COO Sells Stock Options for $476,000
- Stock Option Transaction: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options, converting them into common shares for a total transaction value of approximately $476,000, indicating the company's active engagement in the capital markets.
- Ownership Change Analysis: While Goin's direct ownership of common stock has dropped to zero, she retains 17,219 outstanding options, preserving her economic interest in the company, particularly against the backdrop of rising stock prices.
- Market Performance Review: The shares were sold at a weighted average price of around $110.73, while the stock price surged to $148.21 as of June 26, 2026, reflecting nearly a 620% annual increase, showcasing market optimism regarding QTORIN.
- Regulatory Progress and Market Outlook: Palvella recently received FDA rolling review for its New Drug Application for QTORIN, with plans to complete the submission in the second half of 2026, and management aims to leverage Breakthrough Therapy and Fast Track designations to expedite the approval process, enhancing investor confidence in the company's future.
See More
Palvella Therapeutics Executive Sells Stock Options for $476,000
- Executive Transaction Overview: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options and immediately converted them into common shares for a transaction value of approximately $476,000, indicating proactive management of executive holdings.
- Ownership Change Analysis: While Goin's direct ownership of common stock is now zero, she retains 17,219 outstanding options, preserving her economic interest through potential future share conversions, reflecting confidence in the company's growth trajectory.
- Market Reaction and Stock Performance: The shares were sold at a weighted average price of $110.73, while the stock closed at $148.21 on June 26, 2026, showcasing a nearly 620% increase over the past year, highlighting market optimism surrounding QTORIN.
- Regulatory and Future Outlook: Goin's transaction was executed under a Rule 10b5-1 trading plan adopted on August 19, 2025; despite insider sales, upcoming FDA rolling review and new drug application submission are likely to have a more significant impact on the company's commercialization prospects.
See More
Palvella Receives FDA Rolling Review for Qtorin Application
- FDA Rolling Review: Palvella Therapeutics announced that its new drug application for Qtorin rapamycin has received a rolling review from the FDA, a process designed to expedite the evaluation of drugs for treating microcystic lymphatic malformations, indicating the FDA's recognition of the drug's potential efficacy.
- Therapeutic Potential: Qtorin rapamycin is Palvella's lead candidate, designed to deliver rapamycin directly to pathogenic skin tissue to inhibit disease-driving mTOR signaling, expected to provide a new treatment option for mLM patients who currently have no FDA-approved therapies.
- Clinical Trial Success: In the Phase 3 SELVA trial, Qtorin rapamycin successfully met its primary endpoint, demonstrating its efficacy in treating microcystic lymphatic malformations and laying the groundwork for the upcoming NDA submission.
- Future Plans: Palvella plans to complete the NDA submission in the second half of 2026, further advancing Qtorin's market access, while the drug is also being developed for treating cutaneous venous malformations and clinically significant angiokeratomas, showcasing its broad application potential.
See More
Palvella Receives FDA Rolling Review Approval for QTORIN™ Rapamycin
- FDA Rolling Review: Palvella Therapeutics announced that its New Drug Application (NDA) for QTORIN™ rapamycin has received FDA rolling review approval, with submission expected in the second half of 2026, which will expedite treatment options for over 30,000 patients with microcystic lymphatic malformations.
- Positive Clinical Results: Following encouraging Phase 3 SELVA trial results, Palvella's CEO emphasized the company's commitment to advancing QTORIN™ rapamycin as the first FDA-approved therapy for microcystic LMs, addressing a significant unmet medical need in the market.
- Precision Treatment Strategy: QTORIN™ rapamycin is designed to target pathogenic skin tissue directly, inhibiting the disease-driving mTOR signaling while minimizing systemic exposure, which is expected to significantly enhance the quality of life for patients, particularly children.
- Regulatory Advantage Utilization: By leveraging FDA's Fast Track, Breakthrough Therapy, and Orphan Drug designations, Palvella can submit completed sections of the NDA for review concurrently, providing a more efficient approval pathway and strengthening its competitive position in the market.
See More
Palvella on Track to Submit NDA for QTORIN™ in 2026
- NDA Submission Progress: Palvella Therapeutics is on track to submit an NDA for QTORIN™ 3.9% rapamycin anhydrous gel in the second half of 2026, aiming to provide the first FDA-approved therapy for over 30,000 individuals with microcystic lymphatic malformations in the U.S., significantly improving patient quality of life.
- Clinical Study Results: During the pre-NDA meeting with the FDA, Palvella presented efficacy and safety data from its Phase 3 SELVA study, highlighting QTORIN™'s potential as a standard treatment for microcystic lymphatic malformations, addressing a critical unmet medical need in the market.
- Regulatory Support: QTORIN™ rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, indicating its significant potential in treating microcystic lymphatic malformations, which is expected to expedite its market entry and meet urgent patient needs.
- Future Development Strategy: Palvella plans to include supportive clinical data from the Phase 2 study and real-world evidence in its NDA submission to strengthen the application, further solidifying its market position in the rare disease treatment landscape.
See More
Palvella Therapeutics Executive Exercises Stock Options
- Stock Option Exercise: Kathleen Goin, COO of Palvella Therapeutics, exercised and sold 4,302 common shares on June 17, 2026, for approximately $476,000 at an average price of $110.73 per share, indicating executive confidence in the company's future stock performance.
- FDA Review Progress: The company recently received FDA rolling review for its New Drug Application for QTORIN rapamycin, suggesting a positive regulatory outlook for its rare skin disease treatment, which could expedite the approval process and enhance market competitiveness.
- Strong Market Performance: Palvella's shares have surged nearly 620% over the past year, reflecting investor optimism regarding its lead therapy QTORIN, further solidifying the company's position in the rare disease treatment market.
- Strategic Market Shift: The recent move of Palvella's shares to the Nasdaq Global Market is expected to increase the company's visibility, aiding in garnering more attention and investment for its potential first-in-disease therapies.
See More
Palvella COO Sells Stock Options for $476,000
- Stock Option Transaction: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options, converting them into common shares for a total transaction value of approximately $476,000, indicating the company's active engagement in the capital markets.
- Ownership Change Analysis: While Goin's direct ownership of common stock has dropped to zero, she retains 17,219 outstanding options, preserving her economic interest in the company, particularly against the backdrop of rising stock prices.
- Market Performance Review: The shares were sold at a weighted average price of around $110.73, while the stock price surged to $148.21 as of June 26, 2026, reflecting nearly a 620% annual increase, showcasing market optimism regarding QTORIN.
- Regulatory Progress and Market Outlook: Palvella recently received FDA rolling review for its New Drug Application for QTORIN, with plans to complete the submission in the second half of 2026, and management aims to leverage Breakthrough Therapy and Fast Track designations to expedite the approval process, enhancing investor confidence in the company's future.
See More
Palvella Therapeutics Executive Sells Stock Options for $476,000
- Executive Transaction Overview: Kathleen Goin, COO of Palvella Therapeutics, exercised 4,302 stock options and immediately converted them into common shares for a transaction value of approximately $476,000, indicating proactive management of executive holdings.
- Ownership Change Analysis: While Goin's direct ownership of common stock is now zero, she retains 17,219 outstanding options, preserving her economic interest through potential future share conversions, reflecting confidence in the company's growth trajectory.
- Market Reaction and Stock Performance: The shares were sold at a weighted average price of $110.73, while the stock closed at $148.21 on June 26, 2026, showcasing a nearly 620% increase over the past year, highlighting market optimism surrounding QTORIN.
- Regulatory and Future Outlook: Goin's transaction was executed under a Rule 10b5-1 trading plan adopted on August 19, 2025; despite insider sales, upcoming FDA rolling review and new drug application submission are likely to have a more significant impact on the company's commercialization prospects.
See More
Palvella Receives FDA Rolling Review for Qtorin Application
- FDA Rolling Review: Palvella Therapeutics announced that its new drug application for Qtorin rapamycin has received a rolling review from the FDA, a process designed to expedite the evaluation of drugs for treating microcystic lymphatic malformations, indicating the FDA's recognition of the drug's potential efficacy.
- Therapeutic Potential: Qtorin rapamycin is Palvella's lead candidate, designed to deliver rapamycin directly to pathogenic skin tissue to inhibit disease-driving mTOR signaling, expected to provide a new treatment option for mLM patients who currently have no FDA-approved therapies.
- Clinical Trial Success: In the Phase 3 SELVA trial, Qtorin rapamycin successfully met its primary endpoint, demonstrating its efficacy in treating microcystic lymphatic malformations and laying the groundwork for the upcoming NDA submission.
- Future Plans: Palvella plans to complete the NDA submission in the second half of 2026, further advancing Qtorin's market access, while the drug is also being developed for treating cutaneous venous malformations and clinically significant angiokeratomas, showcasing its broad application potential.
See More
Palvella Receives FDA Rolling Review Approval for QTORIN™ Rapamycin
- FDA Rolling Review: Palvella Therapeutics announced that its New Drug Application (NDA) for QTORIN™ rapamycin has received FDA rolling review approval, with submission expected in the second half of 2026, which will expedite treatment options for over 30,000 patients with microcystic lymphatic malformations.
- Positive Clinical Results: Following encouraging Phase 3 SELVA trial results, Palvella's CEO emphasized the company's commitment to advancing QTORIN™ rapamycin as the first FDA-approved therapy for microcystic LMs, addressing a significant unmet medical need in the market.
- Precision Treatment Strategy: QTORIN™ rapamycin is designed to target pathogenic skin tissue directly, inhibiting the disease-driving mTOR signaling while minimizing systemic exposure, which is expected to significantly enhance the quality of life for patients, particularly children.
- Regulatory Advantage Utilization: By leveraging FDA's Fast Track, Breakthrough Therapy, and Orphan Drug designations, Palvella can submit completed sections of the NDA for review concurrently, providing a more efficient approval pathway and strengthening its competitive position in the market.
See More
Palvella on Track to Submit NDA for QTORIN™ in 2026
- NDA Submission Progress: Palvella Therapeutics is on track to submit an NDA for QTORIN™ 3.9% rapamycin anhydrous gel in the second half of 2026, aiming to provide the first FDA-approved therapy for over 30,000 individuals with microcystic lymphatic malformations in the U.S., significantly improving patient quality of life.
- Clinical Study Results: During the pre-NDA meeting with the FDA, Palvella presented efficacy and safety data from its Phase 3 SELVA study, highlighting QTORIN™'s potential as a standard treatment for microcystic lymphatic malformations, addressing a critical unmet medical need in the market.
- Regulatory Support: QTORIN™ rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, indicating its significant potential in treating microcystic lymphatic malformations, which is expected to expedite its market entry and meet urgent patient needs.
- Future Development Strategy: Palvella plans to include supportive clinical data from the Phase 2 study and real-world evidence in its NDA submission to strengthen the application, further solidifying its market position in the rare disease treatment landscape.
See More
